Hypertension Management in Diabetic Kidney Disease-Reference-Cited by-同舟云学术

Hypertension Management in Diabetic Kidney Disease

Published:2015-08-01 Issue:3 Volume:28 Page:175-180
ISSN:1040-9165
Container-title:Diabetes Spectrum
language:en
Short-container-title:

Author:

Patney Vikram¹,Whaley-Connell Adam¹²,Bakris George³

Affiliation:

1. University of Missouri Columbia School of Medicine, Department of Medicine, Division of Nephrology and Hypertension, Columbia, MO

2. Research Service, Harry S. Truman Memorial Veterans’ Hospital, Columbia, MO

3. The University of Chicago Medicine, ASH Comprehensive Hypertension Center, Chicago, IL

Abstract

IN BRIEF Hypertension is prevalent in most individuals with diabetic kidney disease (DKD). Failure to treat hypertension appropriately in this subgroup of patients results in an increased risk of cardiovascular morbidity and mortality, as well as a faster progression of kidney disease. The current guidance for appropriate treatment of hypertension in this high-risk population provides an opportunity to improve both kidney and cardiovascular outcomes. This review discusses the current state of evidence-based hypertension management in patients with DKD.

Publisher

American Diabetes Association

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://diabetesjournals.org/spectrum/article-pdf/28/3/175/505086/175.pdf

Reference50 articles.

1. Incidence of treatment for end-stage renal disease among individuals with diabetes in the U.S. continues to decline;Burrows;Diabetes Care,2010

2. Changes in diabetes-related complications in the United States, 1990–2010;Gregg;N Engl J Med,2014

3. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38;U.K. Prospective Diabetes Study Group;BMJ,1998

4. Effect of Losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy;Brenner;N Engl J Med,2001

5. 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in United States;U.S. Renal Data System,2010

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of GLP-1 receptor agonist liraglutide on blood pressure profile, hydration, natriuresis in diabetic patients with severely impaired kidney function;Scientific Reports;2024-02-29

2. The therapeutic effect of mesenchymal stem cells in diabetic kidney disease;Journal of Molecular Medicine;2024-02-29

3. The mechanism of the transient increase of blood pressure caused by GLP-1 receptor agonist liraglutide in diabetic patients with severely impaired kidney function.;2023-07-18

4. Diagnostic value of serum cathepsin S in type 2 diabetic kidney disease;Frontiers in Endocrinology;2023-05-25

5. The Therapeutic Effect of Mesenchymal Stem Cells in Diabetic Kidney Disease;2023-05-12